Literature DB >> 19823753

Evaluation of specific delivery of chimeric phi29 pRNA/siRNA nanoparticles to multiple tumor cells.

Li Li1, Jing Liu, Zhijuan Diao, Dan Shu, Peixuan Guo, Guanxin Shen.   

Abstract

The pRNA (packaging RNA) of bacteriophage phi29 DNA packaging motor has been reported to have novel applications in nanotechnology and nanomedicine. The unique ability of pRNA to form dimers, trimers, hexamers and patterned superstructures via the interaction of two reengineered interlocking loops makes it a promising polyvalent vehicle to load siRNA and other therapeutic molecules and be applied as a therapeutic nanoparticle in tumor therapy. In this study, several tumor cell lines were used to evaluate the previously reported pRNA nanotechnology for specific siRNA delivery and for the silencing of targeted genes. It was found that MCF-7 and HeLa cells, out of twenty-five tested tumor cell lines, expressed high levels of folate receptors and exhibited specific binding of the FITC-folate-pRNA nanoparticles, while the others expressed low levels and thus, for these, delivery was not feasible using folate as a targeting agent. Folate receptor positive tumor cells were then incubated with the chimeric pRNA dimer harboring both the folate-pRNA and the chimeric pRNA/siRNA (survivin). Knock down effects of survivin expression in these tumor cells were detected at the mRNA level by real time-PCR and at the protein level by western blot. Apoptosis was detected by flow cytometry analysis with dual staining of annexinV-FITC and PI. The data suggest that the chimeric pRNA nanoparticles containing folate-pRNA and pRNA/siRNA (survivin) could be specifically taken up by tumor cells through folate receptor-mediated endocytosis, resulting in significant inhibition of both transcription and expression of survivin in tumor cells and triggering cell apoptosis. Using such protein-free nanoparticles as therapeutic reagents would not only allow specific gene delivery and extend the in vivo retaining time but also allow long-term administration of therapeutic particles, therefore avoiding the induction of antibodies caused by repeated treatment for chronic diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19823753      PMCID: PMC2862387          DOI: 10.1039/b903428e

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  52 in total

1.  Three-dimensional interaction of Phi29 pRNA dimer probed by chemical modification interference, cryo-AFM, and cross-linking.

Authors:  Y Mat-Arip; K Garver; C Chen; S Sheng; Z Shao; P Guo
Journal:  J Biol Chem       Date:  2001-05-22       Impact factor: 5.157

2.  Overexpression of folate binding protein in ovarian cancers.

Authors:  G Toffoli; C Cernigoi; A Russo; A Gallo; M Bagnoli; M Boiocchi
Journal:  Int J Cancer       Date:  1997-04-22       Impact factor: 7.396

3.  Bottom-up Assembly of RNA Arrays and Superstructures as Potential Parts in Nanotechnology.

Authors:  Dan Shu; Wulf-Dieter Moll; Zhaoxiang Deng; Chengde Mao; Peixuan Guo
Journal:  Nano Lett       Date:  2004-09       Impact factor: 11.189

Review 4.  RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy.

Authors:  Peixuan Guo
Journal:  J Nanosci Nanotechnol       Date:  2005-12

5.  Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.

Authors:  Jyotsnabaran Halder; Aparna A Kamat; Charles N Landen; Liz Y Han; Susan K Lutgendorf; Yvonne G Lin; William M Merritt; Nicholas B Jennings; Arturo Chavez-Reyes; Robert L Coleman; David M Gershenson; Rosemarie Schmandt; Steven W Cole; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

6.  A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy.

Authors:  R A Olie; A P Simões-Wüst; B Baumann; S H Leech; D Fabbro; R A Stahel; U Zangemeister-Wittke
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

7.  Characterization of a high-affinity folate receptor in normal and malignant human testicular tissue.

Authors:  J Holm; S I Hansen; M Høier-Madsen; T B Christensen; C W Nichols
Journal:  Biosci Rep       Date:  1999-12       Impact factor: 3.840

8.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

9.  Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia.

Authors:  J F Ross; H Wang; F G Behm; P Mathew; M Wu; R Booth; M Ratnam
Journal:  Cancer       Date:  1999-01-15       Impact factor: 6.860

10.  Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells.

Authors:  S Guo; F Huang; P Guo
Journal:  Gene Ther       Date:  2006-05       Impact factor: 5.250

View more
  19 in total

1.  Viral nanoparticles as macromolecular devices for new therapeutic and pharmaceutical approaches.

Authors:  Simone Grasso; Luca Santi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2010-07-06

2.  Three-way junction conformation dictates self-association of phage packaging RNAs.

Authors:  Yumeng Hao; Jeffrey S Kieft
Journal:  RNA Biol       Date:  2016-05-24       Impact factor: 4.652

3.  Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition.

Authors:  Jiehua Zhou; Yi Shu; Peixuan Guo; David D Smith; John J Rossi
Journal:  Methods       Date:  2011-01-20       Impact factor: 3.608

4.  Pharmacological characterization of chemically synthesized monomeric phi29 pRNA nanoparticles for systemic delivery.

Authors:  Sherine Abdelmawla; Songchuan Guo; Limin Zhang; Sai M Pulukuri; Prithviraj Patankar; Patrick Conley; Joseph Trebley; Peixuan Guo; Qi-Xiang Li
Journal:  Mol Ther       Date:  2011-04-05       Impact factor: 11.454

5.  Assembly of therapeutic pRNA-siRNA nanoparticles using bipartite approach.

Authors:  Yi Shu; Mathieu Cinier; Sejal R Fox; Nira Ben-Johnathan; Peixuan Guo
Journal:  Mol Ther       Date:  2011-04-05       Impact factor: 11.454

Review 6.  Assembly of multifunctional phi29 pRNA nanoparticles for specific delivery of siRNA and other therapeutics to targeted cells.

Authors:  Yi Shu; Mathieu Cinier; Dan Shu; Peixuan Guo
Journal:  Methods       Date:  2011-02-12       Impact factor: 3.608

Review 7.  Computational approaches to 3D modeling of RNA.

Authors:  Christian Laing; Tamar Schlick
Journal:  J Phys Condens Matter       Date:  2010-06-15       Impact factor: 2.333

8.  Aptamer-targeted cell-specific RNA interference.

Authors:  Jiehua Zhou; John J Rossi
Journal:  Silence       Date:  2010-02-01

9.  A polyhedron made of tRNAs.

Authors:  Isil Severcan; Cody Geary; Arkadiusz Chworos; Neil Voss; Erica Jacovetty; Luc Jaeger
Journal:  Nat Chem       Date:  2010-07-18       Impact factor: 24.427

10.  Fabrication of pRNA nanoparticles to deliver therapeutic RNAs and bioactive compounds into tumor cells.

Authors:  Yi Shu; Dan Shu; Farzin Haque; Peixuan Guo
Journal:  Nat Protoc       Date:  2013-08-01       Impact factor: 13.491

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.